Monoclonal antibodies that demonstrate specificity for several types of human lung cancer.

Publisher Website
Google Scholar
Abstract
Monoclonal antibodies with selectivity for human lung cancer were produced by immunizing BALB/c mice with an established line of human small cell lung cancer (NCI-H69) and fusing the mouse spleen cells to mouse myeloma line X63-Ag8.653. The resulting hybrid cells were initially screened by immunoautoradiography for production of antibodies that would react with NCI-H69 and another small cell lung cancer line (NCI-H128) but not its autologous B-lymphoblastoid line (NCI-H128BL). Stable monoclonal antibody-producing lines were isolated by repeated cloning. Three independently derived monoclonal antibodies, designated 525A5, 534F8 and 538F12, reacted with 3 of the major types of human lung cancer (small cell, adenocarcinoma, and squamous carcinoma). They did not react with bronchioloalveolar and large cell lung cancers, myeloma, lymphomas, leukemias, osteogeneic sarcoma, mesothelioma, hypernephroma, malignant melanoma, SV-40-transformed human fetal lung cells, skin fibroblast lines, human B-lymphoblastoid lines, human erythrocytes and rodent cells. Interestingly, these antibodies also bound to 3 out of 3 human neuroblastomas and 2 out of 3 breast cancers but failed to react with mouse neuroblastoma and rat pheochromocytoma. The monoclonal antibodies reacted with human small cell lung cancer tumors obtained at autopsy but had insignificant reactions with normal human lung, liver, spleen, and skeletal muscle. Monoclonal antibodies have been generated that react with common antigenic determinants expressed on several lung cancer types, neuroblastoma and some breast cancers, but are not detectable by current assays on a variety of other human tumors or normal adult human tissues. Such antibodies are of potential clinical and biological importance.